Blackstone Life Sciences, Intellia Therapeutics and Cellex Cell Professionals New Company
Blackstone (BX) announced that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company with Intellia Therapeutics (This content is for paid subscribers.